152 related articles for article (PubMed ID: 27042010)
21. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
23. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
[TBL] [Abstract][Full Text] [Related]
24. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
25. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
26. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
27. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
28. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
29. Novel anticancer Hsp90 inhibitor disubstituted pyrazolyl 2-aminopyrimidine compound 7t induces cell cycle arrest and apoptosis via mitochondrial pathway in MCF-7 cells.
Mettu A; Talla V; Naikal SJP
Bioorg Med Chem Lett; 2020 Oct; 30(20):127470. PubMed ID: 32795627
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
32. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
33. Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment.
Dubey R; Makhija R; Sharma A; Sahu A; Asati V
Bioorg Chem; 2024 Aug; 149():107508. PubMed ID: 38850781
[TBL] [Abstract][Full Text] [Related]
34. Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7.
Zhang H; Lin G; Jia S; Zhang Y; Wu J; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
Eur J Med Chem; 2024 Jan; 263():115955. PubMed ID: 38000213
[TBL] [Abstract][Full Text] [Related]
35. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.
Li X; Dean DC; Yuan J; Temple TH; Trent JC; Rosenberg AE; Yu S; Hornicek FJ; Duan Z
Biomed Pharmacother; 2022 May; 149():112888. PubMed ID: 35367753
[TBL] [Abstract][Full Text] [Related]
37. Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7.
Jia M; Wang W; Chen G; Wu T; Zhang T; Zhou Q; Yin J; Li J; Li X; Mao Y; Feng J; Hu M; Li X; He F
Bioorg Med Chem Lett; 2023 Sep; 93():129429. PubMed ID: 37543274
[TBL] [Abstract][Full Text] [Related]
38. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
40. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells.
Kolloch L; Kreinest T; Meisterernst M; Oeckinghaus A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]